| Primary |
| Antibiotic Prophylaxis |
12.0% |
| Product Used For Unknown Indication |
11.6% |
| Pneumonia |
8.3% |
| Drug Use For Unknown Indication |
6.2% |
| Pseudomonas Infection |
6.2% |
| Urinary Tract Infection |
5.4% |
| Neutropenic Sepsis |
5.0% |
| Non-hodgkin's Lymphoma Stage Iv |
5.0% |
| Cystic Fibrosis |
4.1% |
| Pulmonary Tuberculosis |
4.1% |
| Antibiotic Therapy |
3.7% |
| Fracture |
3.7% |
| Pyrexia |
3.7% |
| Scrub Typhus |
3.7% |
| Bronchiectasis |
3.3% |
| Sepsis |
3.3% |
| Systemic Antibacterial Therapy |
2.9% |
| Fibroma |
2.5% |
| Meningitis Bacterial |
2.5% |
| Prophylaxis |
2.5% |
|
| Renal Failure Acute |
20.2% |
| Renal Tubular Necrosis |
9.0% |
| Status Epilepticus |
7.9% |
| Thrombocytopenia |
6.7% |
| Anaphylactic Reaction |
5.6% |
| Rash |
5.6% |
| Wheezing |
5.6% |
| Stevens-johnson Syndrome |
4.5% |
| Urticaria |
4.5% |
| Anaphylactic Shock |
3.4% |
| Convulsion |
3.4% |
| Dehydration |
3.4% |
| Pruritus |
3.4% |
| Toxic Epidermal Necrolysis |
3.4% |
| Altered State Of Consciousness |
2.2% |
| Anal Haemorrhage |
2.2% |
| Clostridium Difficile Colitis |
2.2% |
| Delirium |
2.2% |
| Diarrhoea Haemorrhagic |
2.2% |
| Drug Interaction |
2.2% |
|
| Secondary |
| Product Used For Unknown Indication |
26.4% |
| Drug Use For Unknown Indication |
22.9% |
| Pyrexia |
6.7% |
| Pneumonia |
5.1% |
| Pseudomonas Infection |
5.1% |
| Antibiotic Therapy |
3.6% |
| Diabetic Foot |
3.4% |
| Prophylaxis |
3.1% |
| Bacteraemia |
2.8% |
| Cystic Fibrosis |
2.3% |
| Sedation |
2.3% |
| Acute Myeloid Leukaemia |
2.2% |
| Meningitis Bacterial |
1.9% |
| Neutropenic Sepsis |
1.9% |
| Non-hodgkin's Lymphoma Stage Iv |
1.9% |
| Immunosuppression |
1.9% |
| Hypertension |
1.8% |
| Staphylococcal Infection |
1.8% |
| Febrile Neutropenia |
1.5% |
| Endophthalmitis |
1.4% |
|
| Renal Failure Acute |
16.6% |
| Toxic Epidermal Necrolysis |
16.6% |
| Renal Tubular Necrosis |
6.0% |
| Stevens-johnson Syndrome |
5.3% |
| Thrombocytopenia |
5.3% |
| Multi-organ Failure |
4.0% |
| Renal Failure |
4.0% |
| Syncope |
4.0% |
| Vitamin K Deficiency |
4.0% |
| Wheezing |
4.0% |
| Clostridium Difficile Colitis |
3.3% |
| Death |
3.3% |
| Histiocytosis Haematophagic |
3.3% |
| Intestinal Obstruction |
3.3% |
| Sepsis |
3.3% |
| Splenic Infarction |
3.3% |
| Drug Ineffective |
2.6% |
| Pancytopenia |
2.6% |
| Pyrexia |
2.6% |
| Renal Impairment |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
34.0% |
| Drug Use For Unknown Indication |
15.3% |
| Prophylaxis |
8.5% |
| Infection Prophylaxis |
6.5% |
| Acute Myeloid Leukaemia |
5.4% |
| Pyrexia |
3.6% |
| Acute Lymphocytic Leukaemia |
3.2% |
| Pneumonia |
2.8% |
| Bone Marrow Conditioning Regimen |
2.4% |
| Prophylaxis Against Graft Versus Host Disease |
2.3% |
| Febrile Neutropenia |
2.2% |
| Hypertension |
2.0% |
| Infection |
1.8% |
| Antifungal Prophylaxis |
1.8% |
| Pain |
1.7% |
| Nausea |
1.4% |
| Constipation |
1.4% |
| Chemotherapy |
1.3% |
| Multiple Myeloma |
1.2% |
| Sepsis |
1.2% |
|
| Sepsis |
10.7% |
| White Blood Cell Count Decreased |
8.7% |
| Septic Shock |
8.1% |
| Vomiting |
7.9% |
| Renal Failure Acute |
7.6% |
| Pyrexia |
7.0% |
| Respiratory Failure |
6.8% |
| Thrombocytopenia |
6.4% |
| Renal Impairment |
5.6% |
| Pneumonia |
4.8% |
| Renal Failure |
4.5% |
| Death |
3.1% |
| Drug Ineffective |
3.1% |
| Multi-organ Failure |
2.5% |
| Platelet Count Decreased |
2.5% |
| Ventricular Tachycardia |
2.5% |
| Renal Failure Chronic |
2.3% |
| Febrile Neutropenia |
2.1% |
| Thrombotic Microangiopathy |
2.1% |
| Neutropenia |
1.9% |
|
| Interacting |
| Cystic Fibrosis |
64.7% |
| Diabetes Mellitus |
5.9% |
| Dyslipidaemia |
5.9% |
| H1n1 Influenza |
5.9% |
| Hypertension |
5.9% |
| Hyperuricaemia |
5.9% |
| Pulmonary Hypertension |
5.9% |
|
| Drug Eruption |
33.3% |
| Drug Interaction |
33.3% |
| Rectal Haemorrhage |
33.3% |
|
